FDA-Approved Pancreatic Cancer Drug Rasonque Faces Patient Access Barriers
Source Summary
The FDA approved Rasonque, a new pancreatic cancer drug, marking a research breakthrough. However, some patients seeking immediate access to the treatment have encountered obstacles in obtaining it.
Why it matters
FDA approval of a new pancreatic cancer treatment represents a medical advance, but access barriers demonstrate that regulatory approval alone does not guarantee patients can obtain approved drugs.
